ConductScience.org, home
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
API referenceFor AI assistants

Trial · NCT02544633

Results by group89

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 89

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Objective Response RateMET Activating Mutations in Tumor Tissue10.795% Confidence Interval 2.27 to 28.23percentage of participants
Objective Response RateMET Gene Amplifications in Tumor Tissue15.095% Confidence Interval 3.21 to 37.89percentage of participants
Objective Response RateMET Activating Mutations in ctDNA25.095% Confidence Interval 3.19 to 65.09percentage of participants
Objective Response RateMET Gene Amplifications in ctDNA0.095% Confidence Interval 0.00 to 26.46percentage of participants
Duration of ResponseMET Activating Mutations in Tumor Tissue8595% Confidence Interval 82 to 132days
Duration of ResponseMET Gene Amplifications in Tumor Tissue17095% Confidence Interval 120 to 170days
Duration of ResponseMET Activating Mutations in ctDNANA95% Confidence Interval 77 to NAdays
Progression Free SurvivalMET Activating Mutations in Tumor Tissue3.9595% Confidence Interval 2.11 to 4.18months
Progression Free SurvivalMET Gene Amplifications in Tumor Tissue4.8495% Confidence Interval 1.35 to 5.53months
Progression Free SurvivalMET Activating Mutations in ctDNA3.3995% Confidence Interval 1.28 to NAmonths
Progression Free SurvivalMET Gene Amplifications in ctDNA2.7695% Confidence Interval 1.48 to 4.01months
1-Year Survival RateMET Activating Mutations in Tumor Tissue50.4795% Confidence Interval 27.49 to 69.62percentage
1-Year Survival RateMET Gene Amplifications in Tumor Tissue34.9295% Confidence Interval 14.05 to 56.89percentage
1-Year Survival RateMET Activating Mutations in ctDNA54.6995% Confidence Interval 13.72 to 83.24percentage
1-Year Survival RateMET Gene Amplifications in ctDNA13.8995% Confidence Interval 0.86 to 44.05percentage
Overall SurvivalMET Activating Mutations in Tumor Tissue16.3295% Confidence Interval 4.01 to NAmonths
Overall SurvivalMET Gene Amplifications in Tumor Tissue7.0495% Confidence Interval 1.84 to 14.93months
Overall SurvivalMET Activating Mutations in ctDNANA95% Confidence Interval .89 to NAmonths
Overall SurvivalMET Gene Amplifications in ctDNA4.0895% Confidence Interval 1.22 to 11.05months
Number of Patients Experiencing Treatment-emergent Adverse EventsMET Activating Mutations in Tumor Tissue28Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02544633/results

API referenceFor AI assistants